

Experience of MTZ Clinical Research in Biosimilarity

Phase I

Lp.	Therapeutic /Chemical subgroup	Chemical substance	Indication / Population
1	Antithrombotic agents	Enoxaparin sodium	Healthy subjects
2	Monoclonal antibodies	Adalimumab	Healthy subjects
3	Monoclonal antibodies	Rituximab	Non-Hodgkin Lymphoma
4	Monoclonal antibodies	Rituximab	Rheumatoid arthritis

Phase III

Lp.	Therapeutic /Chemical subgroup	Chemical substance	Indication / Population
5	Monoclonal antibodies	Adalimumab	Plaque Psoriasis
6	Monoclonal antibodies	Adalimumab	Plaque Psoriasis
7	Monoclonal antibodies	Adalimumab	Plaque Psoriasis
8	Monoclonal antibodies	Adalimumab	Plaque Psoriasis
9	Monoclonal antibodies	Adalimumab	Rheumatoid arthritis
10	Monoclonal antibodies	Bevacizumab	Non-small cell Lung Cancer
11	TNF- α inhibitors	Etanercept	Plaque Psoriasis
12	TNF- α inhibitors	Etanercept	Rheumatoid arthritis
13	Monoclonal antibodies	Infliximab	Rheumatoid arthritis
14	Peptide hormone	Insulin glargine	Type 2 diabetes mellitus
15	Granulocyte colony-stimulating factor	Pegfilgrastim	Neutropenia
16	Granulocyte colony-stimulating factor	Pegfilgrastin	Neutropenia
17	Monoclonal antibodies	Rituximab	Rheumatoid arthritis

Date of issue: May 2019

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN

